Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab
Observational
Time Perspective: Prospective
Validate the utility of an IgE anti-cetuximab test in the treatment strategy
We hypothesize that a positive specific IgE assay predicts the occurrence of an allergic reaction during the first dose of cetuximab. Thus, in population areas where the prevalence of specific IgE positive plasma is higher, the use of alternative therapies in patients with a positive test would reduce the incidence of anaphylactic reactions to cetuximab. If the use of specific IgE anti-cetuximab in the treatment strategy is effective, there will be reduction in the incidence of anaphylaxis to cetuximab in the participating centers.
3 years
No
GERVAIS Radj, MD
Principal Investigator
Centre François Baclesse
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
IgES
NCT01436617
January 2010
March 2013
Name | Location |
---|